Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Status and phase: Completed; Phase 2

Conditions: Neuroendocrine Tumor

Treatments: Drug: Pazopanib

Study type: Interventional

Funder types: Other

Identifiers

NCT01099540

2009-09-090

Details and patient eligibility

About

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion criteria

• poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

37 participants in 1 patient group

Pazopanib

Experimental group

Treatment:

Drug: Pazopanib